⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma

Official Title: An Open-Label, Single-arm, Phase I Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma

Study ID: NCT01402440

Interventions

AEB071

Study Description

Brief Summary: This study has two phases, a dose escalation phase and a dose expansion phase. For dose escalation, the primary objective is to estimate the maximum tolerated dose of AEB071 in patients with diffuse large b-cell lymphoma. The endpoint for this objective will be occurrence of Dose Limiting Toxicity. For dose expansion, the primary objective is to characterize the safety and tolerability of the maximum tolerated dose or recommended phase 2 dose of AEB071 in patients with diffuse large b-cell lymphoma. The endpoints for this objective will be occurrence of Adverse Events (AEs), Serious Adverse Events (SAEs), assessment of clinical laboratory values, and vital sign measurements.

Detailed Description:

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

City of Hope National Medical Center, Duarte, California, United States

Washington University School of Medicine Div. of Medical Oncology, Saint Louis, Missouri, United States

Hackensack University Medical Center Hackensack (SC), Hackensack, New Jersey, United States

Memorial Sloan Kettering Cancer Center MSK 2, New York, New York, United States

Ohio State Comprehensive Cancer Center/James Cancer Hospital Ohio State, Columbus, Ohio, United States

University of Texas/MD Anderson Cancer Center SC Location, Houston, Texas, United States

Novartis Investigative Site, Creteil, , France

Novartis Investigative Site, Lille Cedex, , France

Novartis Investigative Site, Pierre-Benite Cédex, , France

Novartis Investigative Site, Rouen Cedex 1, , France

Novartis Investigative Site, Berlin, , Germany

Novartis Investigative Site, Muenchen, , Germany

Novartis Investigative Site, Shatin, New Territories, , Hong Kong

Novartis Investigative Site, Milano, MI, Italy

Novartis Investigative Site, Torino, TO, Italy

Novartis Investigative Site, Seoul, Korea, Korea, Republic of

Novartis Investigative Site, Amsterdam, , Netherlands

Novartis Investigative Site, Groningen, , Netherlands

Novartis Investigative Site, Rotterdam, , Netherlands

Novartis Investigative Site, Rotterdam, , Netherlands

Novartis Investigative Site, Barcelona, Catalunya, Spain

Novartis Investigative Site, Barcelona, , Spain

Novartis Investigative Site, Taipei, , Taiwan

Novartis Investigative Site, Manchester, , United Kingdom

Contact Details

Name: Novartis Pharmaceuticals

Affiliation: Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Name: Novarts Pharmaceuticals

Affiliation: Novarts Pharmaceuticals

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: